Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7603
Reference
Drug alert 18/2022
Name
Drug alert class 4 – 18 2022 – Caution in use - class 4 medicines defect information: caution in use – Pfizer Ltd Depo-Medrone with Lidocaine 40mg/ml (1ml and 2ml vials – single vial preparations)
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DEFECT INFORMATION
Description
Pfizer Limited have informed the MHRA that an outdated version of the Patient Information Leaflet (PIL) has been included in the packaging of the above mentioned batches of Depo-Medrone with Lidocaine (Methylprednisolone acetate and Lidocaine hydrochloride) 40 mg/mL 1 mL and 2 mL vials (single vial presentations) to the UK market.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2022-04-21 00:00:00
Click to go back to homepage